<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Clinical Trials</title>

<script src="site_libs/header-attrs-2.25/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<script src="site_libs/navigation-1.1/codefolding.js"></script>
<link href="site_libs/highlightjs-9.12.0/default.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<script src="site_libs/htmlwidgets-1.6.3/htmlwidgets.js"></script>
<script src="site_libs/plotly-binding-4.10.3/plotly.js"></script>
<script src="site_libs/typedarray-0.1/typedarray.min.js"></script>
<link href="site_libs/crosstalk-1.2.1/css/crosstalk.min.css" rel="stylesheet" />
<script src="site_libs/crosstalk-1.2.1/js/crosstalk.min.js"></script>
<link href="site_libs/plotly-htmlwidgets-css-2.11.1/plotly-htmlwidgets.css" rel="stylesheet" />
<script src="site_libs/plotly-main-2.11.1/plotly-latest.min.js"></script>
<link href="site_libs/font-awesome-6.4.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.2/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Home</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="Introduction.html">Introduction</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Analysis
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="Data.html">Data Sources</a>
    </li>
    <li>
      <a href="EDA.html">Exploratory Analysis</a>
    </li>
    <li>
      <a href="Preliminary_analysis.html">Preliminary Analysis</a>
    </li>
  </ul>
</li>
<li>
  <a href="Model.html">Model</a>
</li>
<li>
  <a href="Clinical_trials.html">Clinical Trials</a>
</li>
<li>
  <a href="Conclusion.html">Conclusion</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Shiny
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://yigebian.shinyapps.io/Demographic_shiny/">Demographic</a>
    </li>
    <li>
      <a href="https://yigebian.shinyapps.io/ClinicalTrials_shiny/">Clinical Trials</a>
    </li>
  </ul>
</li>
<li>
  <a>
    <span class="fa fa-envelope fa-lg"></span>
     
  </a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-github fa-lg"></span>
     
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://github.com/MiaYum/Alzheimers_Disease_New_Hope">Website Repository</a>
    </li>
    <li>
      <a href="https://github.com/YigeBian/Alzheimers_Disease_New_Hope_Shiny">Shiny Repository</a>
    </li>
  </ul>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">

<div class="btn-group pull-right float-right">
<button type="button" class="btn btn-default btn-xs btn-secondary btn-sm dropdown-toggle" data-toggle="dropdown" data-bs-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu dropdown-menu-right" style="min-width: 50px;">
<li><a id="rmd-show-all-code" href="#">Show All Code</a></li>
<li><a id="rmd-hide-all-code" href="#">Hide All Code</a></li>
</ul>
</div>



<h1 class="title toc-ignore">Clinical Trials</h1>

</div>


<div id="clinical-trials-pipeline" class="section level1">
<h1>Clinical Trials Pipeline</h1>
<p>In our quest to deepen the understanding of Alzheimer’s disease and
its treatment landscape, we have developed an innovative Shiny
application designed to visualize the clinical trials of Alzheimer’s
drugs across the United States. This interactive tool is a significant
stride in making complex trial data accessible, which label all trials
on the map and have regional statistics based on zoom size. The
following screenshot offers a glimpse into the app’s capabilities, and
the full dashboard can be accessed [here].</p>
<p><img src="project_image/shiny_CT1.png" style="width:85%"></p>
</div>
<div id="lecanemab-and-donanemab" class="section level1">
<h1>Lecanemab and Donanemab</h1>
<div id="participants-baseline-demographics-for-both-drugs"
class="section level2">
<h2>Participants’ Baseline Demographics for both drugs</h2>
<pre class="r"><code>sex_df=
  readxl::read_excel(&quot;data/newdrugdemographic.xlsx&quot;,sheet=&quot;Sex&quot;, range = &quot;A1:C5&quot;) |&gt; 
  janitor::clean_names()
sex_df |&gt; 
  plot_ly(x=~drug, y=~sex_prop, type = &quot;bar&quot;, color = ~sex) |&gt; 
  layout(barmode = &quot;stack&quot;,
         title = &quot;Distribution of Participants&#39; Baseline Sex by drugs&quot;,
         xaxis = list(title = &quot;Drug&quot;),
         yaxis = list(title = &quot;Percentage (%)&quot;),
         width=500)</code></pre>
<div class="plotly html-widget html-fill-item" id="htmlwidget-23ccdfbc1675f2a02e94" style="width:90%;height:345.6px;"></div>
<script type="application/json" data-for="htmlwidget-23ccdfbc1675f2a02e94">{"x":{"visdat":{"142071254581":["function () ","plotlyVisDat"]},"cur_data":"142071254581","attrs":{"142071254581":{"x":{},"y":{},"color":{},"alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"}},"layout":{"width":500,"margin":{"b":40,"l":60,"t":25,"r":10},"barmode":"stack","title":"Distribution of Participants' Baseline Sex by drugs","xaxis":{"domain":[0,1],"automargin":true,"title":"Drug","type":"category","categoryorder":"array","categoryarray":["Donanemab","Lecanemab"]},"yaxis":{"domain":[0,1],"automargin":true,"title":"Percentage (%)"},"hovermode":"closest","showlegend":true},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"data":[{"x":["Lecanemab","Donanemab"],"y":[51.600000000000001,56.5],"type":"bar","name":"Female","marker":{"color":"rgba(102,194,165,1)","line":{"color":"rgba(102,194,165,1)"}},"textfont":{"color":"rgba(102,194,165,1)"},"error_y":{"color":"rgba(102,194,165,1)"},"error_x":{"color":"rgba(102,194,165,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Lecanemab","Donanemab"],"y":[48.399999999999999,43.5],"type":"bar","name":"Male","marker":{"color":"rgba(141,160,203,1)","line":{"color":"rgba(141,160,203,1)"}},"textfont":{"color":"rgba(141,160,203,1)"},"error_y":{"color":"rgba(141,160,203,1)"},"error_x":{"color":"rgba(141,160,203,1)"},"xaxis":"x","yaxis":"y","frame":null}],"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<ul>
<li>From the plot, we can see that there are more female participants in
Donanemab’s clinical trial than that in Lecanemab’s clinical trial.</li>
</ul>
<pre class="r"><code>race_df=
  readxl::read_excel(&quot;data/newdrugdemographic.xlsx&quot;,sheet=&quot;Race&quot;, range = &quot;A1:C9&quot;) |&gt; 
  janitor::clean_names()
race_df |&gt; 
  mutate(race = fct_reorder(race, -race_prop)) |&gt;
  plot_ly(x=~drug, y=~race_prop, type = &quot;bar&quot;, color = ~race) |&gt; 
  layout(barmode = &quot;stack&quot;,
         title = &quot;Distribution of Participants&#39; Baseline Race by drugs&quot;,
         xaxis = list(title = &quot;Drug&quot;),
         yaxis = list(title = &quot;Percentage (%)&quot;),
         width=500)</code></pre>
<div class="plotly html-widget html-fill-item" id="htmlwidget-0ff2ca4f6efa321ff24d" style="width:90%;height:345.6px;"></div>
<script type="application/json" data-for="htmlwidget-0ff2ca4f6efa321ff24d">{"x":{"visdat":{"142072fd23bf8":["function () ","plotlyVisDat"]},"cur_data":"142072fd23bf8","attrs":{"142072fd23bf8":{"x":{},"y":{},"color":{},"alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"}},"layout":{"width":500,"margin":{"b":40,"l":60,"t":25,"r":10},"barmode":"stack","title":"Distribution of Participants' Baseline Race by drugs","xaxis":{"domain":[0,1],"automargin":true,"title":"Drug","type":"category","categoryorder":"array","categoryarray":["Donanemab","Lecanemab"]},"yaxis":{"domain":[0,1],"automargin":true,"title":"Percentage (%)"},"hovermode":"closest","showlegend":true},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"data":[{"x":["Lecanemab","Donanemab"],"y":[76.299999999999997,90],"type":"bar","name":"White","marker":{"color":"rgba(102,194,165,1)","line":{"color":"rgba(102,194,165,1)"}},"textfont":{"color":"rgba(102,194,165,1)"},"error_y":{"color":"rgba(102,194,165,1)"},"error_x":{"color":"rgba(102,194,165,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Lecanemab","Donanemab"],"y":[17.100000000000001,7.2999999999999998],"type":"bar","name":"Asian","marker":{"color":"rgba(252,141,98,1)","line":{"color":"rgba(252,141,98,1)"}},"textfont":{"color":"rgba(252,141,98,1)"},"error_y":{"color":"rgba(252,141,98,1)"},"error_x":{"color":"rgba(252,141,98,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Lecanemab","Donanemab"],"y":[2.2999999999999998,2.5],"type":"bar","name":"Black","marker":{"color":"rgba(141,160,203,1)","line":{"color":"rgba(141,160,203,1)"}},"textfont":{"color":"rgba(141,160,203,1)"},"error_y":{"color":"rgba(141,160,203,1)"},"error_x":{"color":"rgba(141,160,203,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Lecanemab","Donanemab"],"y":[4.2999999999999998,0.20000000000000001],"type":"bar","name":"Other or Missing","marker":{"color":"rgba(231,138,195,1)","line":{"color":"rgba(231,138,195,1)"}},"textfont":{"color":"rgba(231,138,195,1)"},"error_y":{"color":"rgba(231,138,195,1)"},"error_x":{"color":"rgba(231,138,195,1)"},"xaxis":"x","yaxis":"y","frame":null}],"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<ul>
<li>From the plot, we can see there is more diversity in Lecanemab’s
clinical trial. Races other than white occupies a larger proportion of
participants in Lecanemab’s clinical trial than that in Donanemab’s
clinical trial than that in Lecanemab’s clinical trial, especially
Asians.</li>
</ul>
<pre class="r"><code>subplot(sex_df |&gt; 
  plot_ly(x=~drug, y=~sex_prop, type = &quot;bar&quot;, color = ~sex) |&gt; 
  layout(barmode = &quot;stack&quot;,
         title = &quot;Distribution of Participants&#39; Baseline Sex by drugs&quot;,
         xaxis = list(title = &quot;Drug&quot;),
         yaxis = list(title = &quot;Percentage (%)&quot;),
         width=500),
  race_df |&gt; 
  mutate(race = fct_reorder(race, -race_prop)) |&gt;
  plot_ly(x=~drug, y=~race_prop, type = &quot;bar&quot;, color = ~race) |&gt; 
  layout(barmode = &quot;stack&quot;,
         title = &quot;Distribution of Participants&#39; Baseline Race by drugs&quot;,
         xaxis = list(title = &quot;Drug&quot;),
         yaxis = list(title = &quot;Percentage (%)&quot;),
         width=500))</code></pre>
<div id="htmlwidget-ecd80902baa7b7191660" style="width:500px;height:345.6px;" class="plotly html-widget"></div>
<script type="application/json" data-for="htmlwidget-ecd80902baa7b7191660">{"x":{"data":[{"x":["Lecanemab","Donanemab"],"y":[51.600000000000001,56.5],"type":"bar","name":"Female","marker":{"color":"rgba(102,194,165,1)","line":{"color":"rgba(102,194,165,1)"}},"textfont":{"color":"rgba(102,194,165,1)"},"error_y":{"color":"rgba(102,194,165,1)"},"error_x":{"color":"rgba(102,194,165,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Lecanemab","Donanemab"],"y":[48.399999999999999,43.5],"type":"bar","name":"Male","marker":{"color":"rgba(141,160,203,1)","line":{"color":"rgba(141,160,203,1)"}},"textfont":{"color":"rgba(141,160,203,1)"},"error_y":{"color":"rgba(141,160,203,1)"},"error_x":{"color":"rgba(141,160,203,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Lecanemab","Donanemab"],"y":[76.299999999999997,90],"type":"bar","name":"White","marker":{"color":"rgba(102,194,165,1)","line":{"color":"rgba(102,194,165,1)"}},"textfont":{"color":"rgba(102,194,165,1)"},"error_y":{"color":"rgba(102,194,165,1)"},"error_x":{"color":"rgba(102,194,165,1)"},"xaxis":"x2","yaxis":"y2","frame":null},{"x":["Lecanemab","Donanemab"],"y":[17.100000000000001,7.2999999999999998],"type":"bar","name":"Asian","marker":{"color":"rgba(252,141,98,1)","line":{"color":"rgba(252,141,98,1)"}},"textfont":{"color":"rgba(252,141,98,1)"},"error_y":{"color":"rgba(252,141,98,1)"},"error_x":{"color":"rgba(252,141,98,1)"},"xaxis":"x2","yaxis":"y2","frame":null},{"x":["Lecanemab","Donanemab"],"y":[2.2999999999999998,2.5],"type":"bar","name":"Black","marker":{"color":"rgba(141,160,203,1)","line":{"color":"rgba(141,160,203,1)"}},"textfont":{"color":"rgba(141,160,203,1)"},"error_y":{"color":"rgba(141,160,203,1)"},"error_x":{"color":"rgba(141,160,203,1)"},"xaxis":"x2","yaxis":"y2","frame":null},{"x":["Lecanemab","Donanemab"],"y":[4.2999999999999998,0.20000000000000001],"type":"bar","name":"Other or Missing","marker":{"color":"rgba(231,138,195,1)","line":{"color":"rgba(231,138,195,1)"}},"textfont":{"color":"rgba(231,138,195,1)"},"error_y":{"color":"rgba(231,138,195,1)"},"error_x":{"color":"rgba(231,138,195,1)"},"xaxis":"x2","yaxis":"y2","frame":null}],"layout":{"xaxis":{"domain":[0,0.47999999999999998],"automargin":true,"type":"category","categoryorder":"array","categoryarray":["Donanemab","Lecanemab"],"anchor":"y"},"xaxis2":{"domain":[0.52000000000000002,1],"automargin":true,"type":"category","categoryorder":"array","categoryarray":["Donanemab","Lecanemab"],"anchor":"y2"},"yaxis2":{"domain":[0,1],"automargin":true,"anchor":"x2"},"yaxis":{"domain":[0,1],"automargin":true,"anchor":"x"},"annotations":[],"shapes":[],"images":[],"width":500,"margin":{"b":40,"l":60,"t":25,"r":10},"barmode":"stack","title":"Distribution of Participants' Baseline Race by drugs","hovermode":"closest","showlegend":true},"attrs":{"142074e1af578":{"x":{},"y":{},"color":{},"alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"},"142074be9c157":{"x":{},"y":{},"color":{},"alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"}},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"subplot":true,"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<pre class="r"><code>combine_mean_sd = function(df, group = &quot;&quot;){
  
  n = df |&gt; filter(str_detect(group, &quot;Low/medium tau&quot;)) |&gt; pull(sample_size) # number in group 1
  m =  df |&gt; filter(str_detect(group, &quot;combined&quot;)) |&gt; pull(sample_size) # number in group 2
  sx = df |&gt; filter(str_detect(group, &quot;Low/medium tau&quot;)) |&gt; pull(sd) # sd of group 1
  sy = df |&gt; filter(str_detect(group, &quot;combined&quot;)) |&gt; pull(sd) # sd of group 2
  x_bar = df |&gt; filter(str_detect(group, &quot;Low/medium tau&quot;)) |&gt; pull(mean) # mean of group 1
  y_bar = df |&gt; filter(str_detect(group, &quot;combined&quot;)) |&gt; pull(mean) # mean of group 2

  combined_mean = (n * x_bar + m * y_bar) / (n + m)
  combined_sd =   sqrt(((n-1)*sx^2+(m-1)*sy^2)/(n+m-1)+(n*m*(x_bar-y_bar)^2)/((n+m)*(n+m-1)))
  combined_samplesize = n + m
  combined_ci_lower = combined_mean - 1.96*combined_sd
  combined_ci_upper = combined_mean + 1.96*combined_sd
  
  return (tibble(
    outcome = df |&gt; head(1) |&gt; pull(outcome),
    group = group,
    mean = combined_mean,
    sd = combined_sd,
    sample_size = combined_samplesize,
    ci_lower = combined_ci_lower,
    ci_upper = combined_ci_upper,
    time = 0))}</code></pre>
<pre class="r"><code>iADRS &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;1&quot;)
CDR_SB &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;2&quot;)
ADCS_iADL &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;3&quot;)
ADAS_Cog13 &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;4&quot;)
MMSE &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;5&quot;)

lec_result &lt;- read_excel(&quot;data/Lecanemab.xlsx&quot;, sheet = &quot;result&quot;) |&gt;
  filter(time == 0,
         outcome %in% c(&quot;CDR-SB&quot;, &quot;ADAS-Cog14&quot;, &quot;MMSE&quot;)) |&gt;
  mutate(drug = &quot;Lecanemab&quot;,
         ci_lower = mean - 1.96*sd,
         ci_upper = mean + 1.96*sd) |&gt;
  select(drug, everything())

don_result = bind_rows(
  combine_mean_sd(CDR_SB |&gt; filter(time == 0, str_detect(group, &quot;Donanemab&quot;)), &quot;Donanemab&quot;),
  combine_mean_sd(CDR_SB |&gt; filter(time == 0, str_detect(group, &quot;Placebo&quot;)), &quot;Placebo&quot;),
  combine_mean_sd(ADAS_Cog13 |&gt; filter(time == 0, str_detect(group, &quot;Donanemab&quot;)), &quot;Donanemab&quot;),
  combine_mean_sd(ADAS_Cog13 |&gt; filter(time == 0, str_detect(group, &quot;Placebo&quot;)), &quot;Placebo&quot;),
  combine_mean_sd(MMSE |&gt; filter(time == 0, str_detect(group, &quot;Donanemab&quot;)), &quot;Donanemab&quot;),
  combine_mean_sd(MMSE |&gt; filter(time == 0, str_detect(group, &quot;Placebo&quot;)), &quot;Placebo&quot;)
  ) |&gt;
  mutate(drug = &quot;Donanemab&quot;) |&gt;
  select(drug, everything())


ggplot(bind_rows(lec_result, don_result) |&gt; filter (!(outcome %in% c(&quot;CDR-SB&quot;, &quot;MMSE&quot;) &amp; group == &quot;Placebo&quot;)), aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.7) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  facet_wrap(~outcome, scales = &quot;free_y&quot;) +
  labs(title = &quot;Mean with 95% CI over Time&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal()</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-6-1.png" width="90%" /></p>
</div>
<div id="donanemab" class="section level2">
<h2>Donanemab</h2>
<p>The outcomes listed include iADRS (Integrated Alzheimer’s Disease
Rating Scale), MMSE (Mini-Mental State Examination), and other clinical
assessments. The table provides valuable insights into the efficacy of
donanemab compared to placebo in slowing the progression of Alzheimer’s
disease over the 76-week period in the different populations
studied.</p>
<p>In the TRAILBLAZER-ALZ 2 clinical trial, the participants were
divided into two populations based on their tau biomarker levels: the
low/medium tau population and the high tau population. Tau is a protein
that accumulates in the brain of people with Alzheimer’s disease and is
associated with neurodegeneration.</p>
<p>The low/medium tau population included participants with mild
cognitive impairment or early Alzheimer’s disease who had low or
intermediate levels of tau biomarkers in their cerebrospinal fluid
(CSF). The high tau population included participants with early
Alzheimer’s disease who had high levels of tau biomarkers in their
CSF.</p>
<p>The combined population included all participants in the trial,
regardless of their tau biomarker levels. The purpose of dividing the
participants into these populations was to assess the efficacy of
donanemab in different subgroups of patients with Alzheimer’s
disease.</p>
<div id="iadrs" class="section level3">
<h3>iADRS</h3>
<p>The Integrated Alzheimer’s Disease Rating Scale (iADRS) is a
comprehensive assessment tool used to measure the progression of
Alzheimer’s disease. It combines the 13-item cognitive subscale of the
Alzheimer’s Disease Assessment Scale (ADAS-Cog13) with the Alzheimer’s
Disease Cooperative Study—Instrumental Activities of Daily Living
(ADCS-iADL). By integrating these measures, the iADRS provides a
holistic evaluation of both cognitive function and daily living
activities in individuals with Alzheimer’s disease.</p>
<pre class="r"><code>iADRS &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;1&quot;)

ggplot(iADRS, aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.7) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  facet_wrap(~outcome, scales = &quot;free_y&quot;) +
  labs(title = &quot;Mean with 95% CI over Time&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal()</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-7-1.png" width="90%" /></p>
<p>The results show that treatment with donanemab resulted in a
statistically significant slowing of clinical progression compared to
placebo in both the low/medium tau and combined populations.</p>
</div>
<div id="cdr-sb" class="section level3">
<h3>CDR-SB</h3>
<p>The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) is a widely
used assessment tool for evaluating the severity of dementia. It is a
composite score derived from the Clinical Dementia Rating (CDR) scale,
which is used to assess the cognitive and functional abilities of
individuals with dementia.</p>
<p>The CDR-SB incorporates ratings across six domains: memory,
orientation, judgment and problem solving, community affairs, home and
hobbies, and personal care. Each domain is rated on a scale from 0 (no
impairment) to 3 (severe impairment), and the total CDR-SB score ranges
from 0 to 18, with higher scores indicating greater clinical
impairment.</p>
<pre class="r"><code>CDR_SB &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;2&quot;)

ggplot(CDR_SB, aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.7) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  facet_wrap(~outcome, scales = &quot;free_y&quot;) +
  labs(title = &quot;Mean with 95% CI over Time&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal()</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-8-1.png" width="90%" /></p>
<p>The trial results demonstrated that treatment with donanemab resulted
in a statistically significant slowing of clinical progression as
measured by the CDR-SB, indicating its potential efficacy in addressing
the symptoms and functional decline associated with early symptomatic
Alzheimer’s disease.</p>
</div>
<div id="adcs-iadl" class="section level3">
<h3>ADCS-iADL</h3>
<p>The Alzheimer’s Disease Cooperative Study—Instrumental Activities of
Daily Living (ADCS-iADL) is a measurement tool used to assess the
functional abilities of individuals with Alzheimer’s disease. It is
designed to evaluate a person’s capacity to perform various instrumental
activities of daily living, such as managing finances, using the
telephone, shopping, preparing meals, doing housework, and managing
medications.</p>
<p>The ADCS-iADL scale provides a structured assessment of a person’s
functional independence and is particularly relevant for evaluating the
impact of Alzheimer’s disease on daily activities beyond basic self-care
tasks. The scale typically ranges from 0 to 59, with lower scores
indicating greater impairment in instrumental activities of daily
living.</p>
<pre class="r"><code>ADCS_iADL &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;3&quot;)

ggplot(ADCS_iADL, aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.7) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  facet_wrap(~outcome, scales = &quot;free_y&quot;) +
  labs(title = &quot;Mean with 95% CI over Time&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal()</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-9-1.png" width="90%" /></p>
<p>In the trial results, changes in ADCS-iADL reflected the impact of
donanemab treatment on patients’ functioning of daily living. By
comparing changes in ADCS-iADL scores between the donanemab group and
the placebo group, it was possible to assess the extent to which
donanemab affected patients’ functioning of daily living.</p>
</div>
<div id="adcs-cgic" class="section level3">
<h3>ADCS-CGIC</h3>
<p>The Alzheimer’s Disease Cooperative Study—Clinical Global Impression
of Change (ADCS-CGIC) is a measurement tool used to assess the overall
clinical status and change over time in individuals with Alzheimer’s
disease. It is designed to provide a global assessment of a patient’s
condition, taking into account cognitive, functional, and behavioral
aspects.</p>
<pre class="r"><code>ADAS_Cog13 &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;4&quot;)

ggplot(ADAS_Cog13, aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.7) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  facet_wrap(~outcome, scales = &quot;free_y&quot;) +
  labs(title = &quot;Mean with 95% CI over Time&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal()</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-10-1.png" width="90%" /></p>
<p>A greater reduction in the least squares mean change from baseline to
76 weeks in the donanemab group compared to the placebo group would
indicate a potential positive effect of donanemab on cognitive
function.</p>
</div>
<div id="mmse" class="section level3">
<h3>MMSE</h3>
<p>The Mini-Mental State Examination (MMSE) is a widely used screening
tool for cognitive impairment and is often employed in clinical and
research settings to assess cognitive function, particularly in the
context of dementia. The MMSE evaluates various cognitive domains,
including orientation, memory, attention, language, and visuospatial
abilities.</p>
<pre class="r"><code>MMSE &lt;- read_excel(&quot;data/Donanemab_.xlsx&quot;, sheet = &quot;5&quot;)

ggplot(MMSE, aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.7) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  facet_wrap(~outcome, scales = &quot;free_y&quot;) +
  labs(title = &quot;Mean with 95% CI over Time&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal()</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-11-1.png" width="90%" /></p>
<p>The MMSE scores provide information about the cognitive function of
the participants in the study. The mean scores and standard deviations
can be used to compare the cognitive performance of the donanemab group
and the placebo group. A higher mean score in the donanemab group
compared to the placebo group would suggest a potential positive effect
of donanemab on cognitive function.</p>
</div>
</div>
<div id="survival-analysis" class="section level2">
<h2>Survival Analysis</h2>
<p>The Phase III trials of Lecanemab and Donanemab both use cumulative
hazard ratio to indicate the risk of progression assessed using CDR-SB
score. The hazard plot for Donanemab is as following</p>
<pre class="r"><code>Don_KM = 
  read_excel(&quot;./Data/Donanemab.xlsx&quot;, sheet = &quot;K-M&quot;, range = &quot;A1:D16&quot;) |&gt;
  janitor::clean_names()

plot_ly(Don_KM |&gt;
                 filter(test == &quot;CDR-SB&quot;) |&gt;
                 pivot_longer(
                   donanemab:placebo,
                   names_to = &quot;drug&quot;,
                   values_to = &quot;ratio&quot;
                 ), x = ~time, y = ~ratio, color = ~drug, line = list(shape = &quot;hv&quot;), colors = &quot;viridis&quot;) |&gt;
  layout(title = &quot;Hazard Plot for Donanemab&quot;,
             xaxis = list(title = &quot;Days from First Infusion&quot;),
             yaxis = list(title = &quot;Percentage of Participants Progression&quot;))</code></pre>
<div class="plotly html-widget html-fill-item" id="htmlwidget-81779a0248ee9feda4a6" style="width:90%;height:345.6px;"></div>
<script type="application/json" data-for="htmlwidget-81779a0248ee9feda4a6">{"x":{"visdat":{"142073bd2da78":["function () ","plotlyVisDat"]},"cur_data":"142073bd2da78","attrs":{"142073bd2da78":{"x":{},"y":{},"line":{"shape":"hv"},"color":{},"colors":"viridis","alpha_stroke":1,"sizes":[10,100],"spans":[1,20]}},"layout":{"margin":{"b":40,"l":60,"t":25,"r":10},"title":"Hazard Plot for Donanemab","xaxis":{"domain":[0,1],"automargin":true,"title":"Days from First Infusion"},"yaxis":{"domain":[0,1],"automargin":true,"title":"Percentage of Participants Progression"},"hovermode":"closest","showlegend":true},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"data":[{"x":[0,60,120,180,240,360,480,540],"y":[0,0,0.035000000000000003,0.070000000000000007,0.078,0.154,0.26300000000000001,0.26300000000000001],"line":{"color":"rgba(68,1,84,1)","shape":"hv"},"type":"scatter","mode":"markers+lines","name":"donanemab","marker":{"color":"rgba(68,1,84,1)","line":{"color":"rgba(68,1,84,1)"}},"textfont":{"color":"rgba(68,1,84,1)"},"error_y":{"color":"rgba(68,1,84,1)"},"error_x":{"color":"rgba(68,1,84,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":[0,60,120,180,240,360,480,540],"y":[0,0,0.081000000000000003,0.14999999999999999,0.17000000000000001,0.246,0.38700000000000001,0.38700000000000001],"line":{"color":"rgba(253,231,37,1)","shape":"hv"},"type":"scatter","mode":"markers+lines","name":"placebo","marker":{"color":"rgba(253,231,37,1)","line":{"color":"rgba(253,231,37,1)"}},"textfont":{"color":"rgba(253,231,37,1)"},"error_y":{"color":"rgba(253,231,37,1)"},"error_x":{"color":"rgba(253,231,37,1)"},"xaxis":"x","yaxis":"y","frame":null}],"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<ul>
<li>The hazard ratio for the combined group of Donanemab was found to be
0.623 with a 95% confidence interval of 0.519 to 0.748, indicating a
significant reduction in the risk associated with the progression of
Alzheimer’s disease as measured by the CDR-SB score. In comparison,
Lecanemab demonstrated a hazard ratio of 0.69, also suggesting a reduced
risk, albeit to a slightly lesser extent than Donanemab. These results
indicate that both drugs are effective in slowing the progression of
Alzheimer’s disease, with Donanemab showing a marginally higher efficacy
in this regard.</li>
</ul>
</div>
<div id="adverse-events" class="section level2">
<h2>Adverse Events</h2>
<div id="general-overview" class="section level3">
<h3>General Overview</h3>
<p>As we progress in our comprehensive exploration of Alzheimer’s
disease and its treatment options, we now turn our focus to a critical
aspect of drug evaluation: the analysis of adverse events associated
with the two promising drugs.</p>
<pre class="r"><code>lec_safety = read_excel(&quot;./Data/Lecanemab.xlsx&quot;, sheet = &quot;safety&quot;, range = &quot;A1:C5&quot;) |&gt;
  janitor::clean_names()

don_safety = read_excel(&quot;./Data/Donanemab.xlsx&quot;, sheet = &quot;safety&quot;, range = &quot;A1:C5&quot;) |&gt;
  janitor::clean_names()

merge_safety = left_join(lec_safety, don_safety, by = &quot;events&quot;)</code></pre>
<pre class="r"><code>plot_ly(merge_safety |&gt;
  mutate(events = fct_reorder(events, -lecanemab)) |&gt;
  pivot_longer(
    lecanemab:donanemab_placebo,
    names_to = &quot;drug&quot;,
    values_to = &quot;cases&quot;
  ), 
  x = ~events, y = ~cases, color = ~drug, type = &#39;bar&#39;, colors = &quot;viridis&quot;)  |&gt;
  layout(title = &quot;Barplot for Adverse Events&quot;,
             xaxis = list(title = &quot;Adverse Event&quot;),
             yaxis = list(title = &quot;Number of participants&quot;))</code></pre>
<div class="plotly html-widget html-fill-item" id="htmlwidget-4cf657e19d5932b2e2de" style="width:90%;height:345.6px;"></div>
<script type="application/json" data-for="htmlwidget-4cf657e19d5932b2e2de">{"x":{"visdat":{"14207397fcbcf":["function () ","plotlyVisDat"]},"cur_data":"14207397fcbcf","attrs":{"14207397fcbcf":{"x":{},"y":{},"color":{},"colors":"viridis","alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"}},"layout":{"margin":{"b":40,"l":60,"t":25,"r":10},"title":"Barplot for Adverse Events","xaxis":{"domain":[0,1],"automargin":true,"title":"Adverse Event","type":"category","categoryorder":"array","categoryarray":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"]},"yaxis":{"domain":[0,1],"automargin":true,"title":"Number of participants"},"hovermode":"closest","showlegend":true},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"data":[{"x":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"],"y":[759,148,69,16],"type":"bar","name":"donanemab","marker":{"color":"rgba(68,1,84,1)","line":{"color":"rgba(68,1,84,1)"}},"textfont":{"color":"rgba(68,1,84,1)"},"error_y":{"color":"rgba(68,1,84,1)"},"error_x":{"color":"rgba(68,1,84,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"],"y":[718,138,32,10],"type":"bar","name":"donanemab_placebo","marker":{"color":"rgba(49,104,142,1)","line":{"color":"rgba(49,104,142,1)"}},"textfont":{"color":"rgba(49,104,142,1)"},"error_y":{"color":"rgba(49,104,142,1)"},"error_x":{"color":"rgba(49,104,142,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"],"y":[798,126,62,6],"type":"bar","name":"lecanemab","marker":{"color":"rgba(53,183,121,1)","line":{"color":"rgba(53,183,121,1)"}},"textfont":{"color":"rgba(53,183,121,1)"},"error_y":{"color":"rgba(53,183,121,1)"},"error_x":{"color":"rgba(53,183,121,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Participants with ≥1 AEs","Participants with ≥1 serious Aes","Study discontinuations due to AEs","Death"],"y":[735,101,26,7],"type":"bar","name":"lecanemab_placebo","marker":{"color":"rgba(253,231,37,1)","line":{"color":"rgba(253,231,37,1)"}},"textfont":{"color":"rgba(253,231,37,1)"},"error_y":{"color":"rgba(253,231,37,1)"},"error_x":{"color":"rgba(253,231,37,1)"},"xaxis":"x","yaxis":"y","frame":null}],"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<ul>
<li>The Lecanemab group experienced a 0.7% death rate (6 cases) compared
to 0.8% (7 cases) in the placebo group, with no deaths linked to
Lecanemab or ARIA. Serious adverse events were slightly higher in the
Lecanemab group at 14.0% (126 cases) versus 11.3% (101 cases) in the
placebo.</li>
<li>For Donanemab, the death rate was 1.9% (16 cases) in the treatment
group against 1.1% (10 cases) in the placebo, with serious adverse
events at 17.4% (148 cases) for Donanemab and 15.8% (138 cases) for the
placebo. These results suggest a similar safety profile for both drugs
compared to their respective placebo groups.</li>
</ul>
<pre class="r"><code>safety_test = function(a, b, c, d, n1, n2){
  RD = round(a/n1 - b/n2, 4)
  RR = round((a/n1)/(b/n2), 4)
  OR = round((a*d)/(b*c), 4)
  Chis = round(prop.test(x = c(a, b), n = c(c, d), alternative = &quot;two.sided&quot;, correct = FALSE)$statistic, 4)
  p_value = round(prop.test(x = c(a, b), n = c(n1, n2), alternative = &quot;two.sided&quot;, correct = FALSE)$p.value, 6)
  return (tibble(Risk_Diff = RD, Risk_Ratio = RR, Odds_Ratio = OR, Xsquared = Chis, P.value = p_value))
  }</code></pre>
<pre class="r"><code>lec_safety_test = safety_test(126, 101, 772, 796, 898, 897)
don_safety_test = safety_test(148, 138, 705, 736, 853, 874)
comp_safety_test = safety_test(126, 148, 772, 705, 898, 853)
safety_merge = bind_rows(lec_safety_test, don_safety_test, comp_safety_test) |&gt;
  mutate(Test = c(&quot;Lec vs Placebo&quot;, &quot;Don vs Placebo&quot;, &quot;Lec vs Don&quot;)) |&gt;
  select(Test, everything())

kable(safety_merge)</code></pre>
<table>
<thead>
<tr class="header">
<th align="left">Test</th>
<th align="right">Risk_Diff</th>
<th align="right">Risk_Ratio</th>
<th align="right">Odds_Ratio</th>
<th align="right">Xsquared</th>
<th align="right">P.value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">Lec vs Placebo</td>
<td align="right">0.0277</td>
<td align="right">1.2461</td>
<td align="right">1.2863</td>
<td align="right">4.1774</td>
<td align="right">0.077332</td>
</tr>
<tr class="even">
<td align="left">Don vs Placebo</td>
<td align="right">0.0156</td>
<td align="right">1.0989</td>
<td align="right">1.1196</td>
<td align="right">1.1387</td>
<td align="right">0.382920</td>
</tr>
<tr class="odd">
<td align="left">Lec vs Don</td>
<td align="right">-0.0332</td>
<td align="right">0.8087</td>
<td align="right">0.7775</td>
<td align="right">5.3225</td>
<td align="right">0.056015</td>
</tr>
</tbody>
</table>
<p>In our statistical analysis of serious adverse events associated with
Lecanemab, Donanemab, and their placebos, we have identified key
findings. With a significance level set at 0.1, our results indicate a
significant difference in serious adverse events between Lecanemab and
its placebo, suggesting a higher risk associated with Lecanemab. In
contrast, Donanemab did not show a significant difference in serious
adverse events compared to its placebo, implying a potentially safer
profile. Additionally, a significant difference was observed between
Lecanemab and Donanemab, highlighting distinct safety profiles for these
drugs.</p>
<p>Then, we further investigate the differences of specific adverse
events for two drugs.</p>
<pre class="r"><code>lec_ae = read_excel(&quot;./Data/Lecanemab.xlsx&quot;, sheet = &quot;AE&quot;, range = &quot;A1:C10&quot;) |&gt;
  janitor::clean_names()

don_ae = read_excel(&quot;./Data/Donanemab.xlsx&quot;, sheet = &quot;AE&quot;, range = &quot;A1:C10&quot;) |&gt;
  janitor::clean_names()

merge_ae = left_join(lec_ae, don_ae, by = &quot;ae&quot;)</code></pre>
<pre class="r"><code>plot_ly(merge_ae |&gt;
  mutate(ae = fct_reorder(ae, donanemab)) |&gt;
  pivot_longer(
    lecanemab:donanemab_placebo,
    names_to = &quot;drug&quot;,
    values_to = &quot;cases&quot;
  ), 
  x = ~ae, y = ~cases, color = ~drug, type = &#39;bar&#39;, colors = &quot;viridis&quot;)  |&gt;
  layout(title = &quot;Barplot for Adverse Events&quot;,
             xaxis = list(title = &quot;Adverse Event&quot;),
             yaxis = list(title = &quot;Number of participants&quot;))</code></pre>
<div class="plotly html-widget html-fill-item" id="htmlwidget-6a03266cd1f81ecb5f9d" style="width:90%;height:345.6px;"></div>
<script type="application/json" data-for="htmlwidget-6a03266cd1f81ecb5f9d">{"x":{"visdat":{"142072ad7b1bf":["function () ","plotlyVisDat"]},"cur_data":"142072ad7b1bf","attrs":{"142072ad7b1bf":{"x":{},"y":{},"color":{},"colors":"viridis","alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"bar"}},"layout":{"margin":{"b":40,"l":60,"t":25,"r":10},"title":"Barplot for Adverse Events","xaxis":{"domain":[0,1],"automargin":true,"title":"Adverse Event","type":"category","categoryorder":"array","categoryarray":["Diarrhea","Urinary tract infection","Arrthralgia","Dizziness","Infusion-related reaction","Fall","Headache","ARIA-H","ARIA-E"]},"yaxis":{"domain":[0,1],"automargin":true,"title":"Number of participants"},"hovermode":"closest","showlegend":true},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"data":[{"x":["Infusion-related reaction","ARIA-E","ARIA-H","Headache","Fall","Urinary tract infection","Arrthralgia","Dizziness","Diarrhea"],"y":[74,205,168,119,114,45,49,53,43],"type":"bar","name":"donanemab","marker":{"color":"rgba(68,1,84,1)","line":{"color":"rgba(68,1,84,1)"}},"textfont":{"color":"rgba(68,1,84,1)"},"error_y":{"color":"rgba(68,1,84,1)"},"error_x":{"color":"rgba(68,1,84,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Infusion-related reaction","ARIA-E","ARIA-H","Headache","Fall","Urinary tract infection","Arrthralgia","Dizziness","Diarrhea"],"y":[4,17,65,86,110,59,42,48,50],"type":"bar","name":"donanemab_placebo","marker":{"color":"rgba(49,104,142,1)","line":{"color":"rgba(49,104,142,1)"}},"textfont":{"color":"rgba(49,104,142,1)"},"error_y":{"color":"rgba(49,104,142,1)"},"error_x":{"color":"rgba(49,104,142,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Infusion-related reaction","ARIA-E","ARIA-H","Headache","Fall","Urinary tract infection","Arrthralgia","Dizziness","Diarrhea"],"y":[237,113,155,100,93,78,53,49,48],"type":"bar","name":"lecanemab","marker":{"color":"rgba(53,183,121,1)","line":{"color":"rgba(53,183,121,1)"}},"textfont":{"color":"rgba(53,183,121,1)"},"error_y":{"color":"rgba(53,183,121,1)"},"error_x":{"color":"rgba(53,183,121,1)"},"xaxis":"x","yaxis":"y","frame":null},{"x":["Infusion-related reaction","ARIA-E","ARIA-H","Headache","Fall","Urinary tract infection","Arrthralgia","Dizziness","Diarrhea"],"y":[66,15,81,73,86,82,62,46,58],"type":"bar","name":"lecanemab_placebo","marker":{"color":"rgba(253,231,37,1)","line":{"color":"rgba(253,231,37,1)"}},"textfont":{"color":"rgba(253,231,37,1)"},"error_y":{"color":"rgba(253,231,37,1)"},"error_x":{"color":"rgba(253,231,37,1)"},"xaxis":"x","yaxis":"y","frame":null}],"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
<p>The barplot clearly shows notable differences in specific adverse
events (such as Infusion-related reactions, ARIA-E/ARIA-H, Urinary tract
infections, and Headaches) between the treatment and placebo groups. To
further evaluate and quantify these observed differences, we will
proceed with a detailed statistical tests to provide a more definitive
understanding of the significance of these adverse events.</p>
</div>
<div id="lecanemab-vs-placebo" class="section level3">
<h3>Lecanemab vs Placebo</h3>
<pre class="r"><code># test = lec_ae |&gt;
#   mutate(p = lecanemab_placebo/sum(lecanemab_placebo))
# chisq.test(test$lecanemab, p = test$p, correct = FALSE) \
lec_ae_result = lec_ae |&gt;
  mutate(testresult = map2(lecanemab, lecanemab_placebo, \(a, b) safety_test(a, b, 898-a, 897-b, 898, 897))) |&gt;
  rename(AE = ae) |&gt;
  unnest(testresult) |&gt;
  select(-lecanemab, -lecanemab_placebo)

kable(lec_ae_result)</code></pre>
<table>
<colgroup>
<col width="34%" />
<col width="13%" />
<col width="14%" />
<col width="14%" />
<col width="11%" />
<col width="11%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">AE</th>
<th align="right">Risk_Diff</th>
<th align="right">Risk_Ratio</th>
<th align="right">Odds_Ratio</th>
<th align="right">Xsquared</th>
<th align="right">P.value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">Infusion-related reaction</td>
<td align="right">0.1903</td>
<td align="right">3.5869</td>
<td align="right">4.5144</td>
<td align="right">177.2332</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">ARIA-E</td>
<td align="right">0.1091</td>
<td align="right">7.5249</td>
<td align="right">8.4642</td>
<td align="right">94.4143</td>
<td align="right">0.000000</td>
</tr>
<tr class="odd">
<td align="left">ARIA-H</td>
<td align="right">0.0823</td>
<td align="right">1.9114</td>
<td align="right">2.1016</td>
<td align="right">36.1979</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">Headache</td>
<td align="right">0.0300</td>
<td align="right">1.3683</td>
<td align="right">1.4145</td>
<td align="right">5.7372</td>
<td align="right">0.031416</td>
</tr>
<tr class="odd">
<td align="left">Fall</td>
<td align="right">0.0077</td>
<td align="right">1.0802</td>
<td align="right">1.0895</td>
<td align="right">0.3691</td>
<td align="right">0.586741</td>
</tr>
<tr class="even">
<td align="left">Urinary tract infection</td>
<td align="right">-0.0046</td>
<td align="right">0.9502</td>
<td align="right">0.9454</td>
<td align="right">0.1396</td>
<td align="right">0.734818</td>
</tr>
<tr class="odd">
<td align="left">Arrthralgia</td>
<td align="right">-0.0101</td>
<td align="right">0.8539</td>
<td align="right">0.8447</td>
<td align="right">0.8755</td>
<td align="right">0.382293</td>
</tr>
<tr class="even">
<td align="left">Dizziness</td>
<td align="right">0.0033</td>
<td align="right">1.0640</td>
<td align="right">1.0677</td>
<td align="right">0.1080</td>
<td align="right">0.756031</td>
</tr>
<tr class="odd">
<td align="left">Diarrhea</td>
<td align="right">-0.0112</td>
<td align="right">0.8267</td>
<td align="right">0.8169</td>
<td align="right">1.1504</td>
<td align="right">0.313832</td>
</tr>
</tbody>
</table>
<ul>
<li>The statistical tests reveals significant differences in the
incidence of infusion-related reactions, ARIA-E/ARIA-H, and headaches
between the Lecanemab and placebo groups. These findings are consistent
with the most common side effects listed on the Lecanemab website,
validating our results. This highlights the need for careful monitoring
of these specific adverse events when considering Lecanemab for
Alzheimer’s treatment, ensuring informed decision-making and optimized
patient care.</li>
</ul>
</div>
<div id="donanemab-vs-placebo" class="section level3">
<h3>Donanemab vs Placebo</h3>
<pre class="r"><code># test = don_ae |&gt;
#   mutate(p = donanemab_placebo/sum(donanemab_placebo))
# chisq.test(test$donanemab, p = test$p, correct = FALSE)

don_ae_result = don_ae |&gt;
  mutate(testresult = map2(donanemab, donanemab_placebo, \(a, b) safety_test(a, b, 853-a, 874-b, 853, 874))) |&gt;
  rename(AE = ae) |&gt;
  unnest(testresult) |&gt;
  select(-donanemab, -donanemab_placebo)

kable(don_ae_result)</code></pre>
<table>
<colgroup>
<col width="34%" />
<col width="13%" />
<col width="14%" />
<col width="14%" />
<col width="11%" />
<col width="11%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">AE</th>
<th align="right">Risk_Diff</th>
<th align="right">Risk_Ratio</th>
<th align="right">Odds_Ratio</th>
<th align="right">Xsquared</th>
<th align="right">P.value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">Infusion-related reaction</td>
<td align="right">0.0822</td>
<td align="right">18.9555</td>
<td align="right">20.6611</td>
<td align="right">74.5253</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">ARIA-E</td>
<td align="right">0.2209</td>
<td align="right">12.3557</td>
<td align="right">15.9482</td>
<td align="right">258.0030</td>
<td align="right">0.000000</td>
</tr>
<tr class="odd">
<td align="left">ARIA-H</td>
<td align="right">0.1226</td>
<td align="right">2.6482</td>
<td align="right">3.0525</td>
<td align="right">76.6319</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">Headache</td>
<td align="right">0.0411</td>
<td align="right">1.4178</td>
<td align="right">1.4855</td>
<td align="right">9.1550</td>
<td align="right">0.008271</td>
</tr>
<tr class="odd">
<td align="left">Fall</td>
<td align="right">0.0078</td>
<td align="right">1.0619</td>
<td align="right">1.0714</td>
<td align="right">0.3132</td>
<td align="right">0.630088</td>
</tr>
<tr class="even">
<td align="left">Urinary tract infection</td>
<td align="right">-0.0148</td>
<td align="right">0.7815</td>
<td align="right">0.7693</td>
<td align="right">1.8867</td>
<td align="right">0.197644</td>
</tr>
<tr class="odd">
<td align="left">Arrthralgia</td>
<td align="right">0.0094</td>
<td align="right">1.1954</td>
<td align="right">1.2073</td>
<td align="right">0.8524</td>
<td align="right">0.382567</td>
</tr>
<tr class="even">
<td align="left">Dizziness</td>
<td align="right">0.0072</td>
<td align="right">1.1314</td>
<td align="right">1.1401</td>
<td align="right">0.4621</td>
<td align="right">0.523000</td>
</tr>
<tr class="odd">
<td align="left">Diarrhea</td>
<td align="right">-0.0068</td>
<td align="right">0.8812</td>
<td align="right">0.8749</td>
<td align="right">0.4388</td>
<td align="right">0.531494</td>
</tr>
</tbody>
</table>
<ul>
<li>The test for comparing Donanemab and its placebo group has similarly
identified significant differences in the occurrence of infusion-related
reactions, ARIA-E/ARIA-H, and headaches. This parallel finding with
Donanemab, mirroring the results observed with Lecanemab, underscores
the importance of these specific adverse events in the context of
Alzheimer’s disease treatments.</li>
</ul>
</div>
<div id="lecanemab-vs-donanemab" class="section level3">
<h3>Lecanemab vs Donanemab</h3>
<pre class="r"><code># test = don_ae |&gt;
#   mutate(p = donanemab_placebo/sum(donanemab_placebo))
# chisq.test(lec_ae$lecanemab, p = test$p, correct = FALSE) 
com_ae =  don_ae |&gt;
  mutate(lecanemab = lec_ae$lecanemab) |&gt;
  select(-donanemab_placebo)

com_ae_test = com_ae |&gt;
  mutate(testresult = map2(lecanemab, donanemab, \(a, b) safety_test(a, b, 898-a, 853-b, 898, 853))) |&gt;
  rename(AE = ae) |&gt;
  unnest(testresult) |&gt;
  select(-donanemab, -lecanemab) |&gt;
  filter(P.value &lt; 0.05)

kable(com_ae_test)</code></pre>
<table>
<colgroup>
<col width="34%" />
<col width="13%" />
<col width="14%" />
<col width="14%" />
<col width="11%" />
<col width="11%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">AE</th>
<th align="right">Risk_Diff</th>
<th align="right">Risk_Ratio</th>
<th align="right">Odds_Ratio</th>
<th align="right">Xsquared</th>
<th align="right">P.value</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">Infusion-related reaction</td>
<td align="right">0.1772</td>
<td align="right">3.0422</td>
<td align="right">3.7744</td>
<td align="right">146.6853</td>
<td align="right">0.000000</td>
</tr>
<tr class="even">
<td align="left">ARIA-E</td>
<td align="right">-0.1145</td>
<td align="right">0.5236</td>
<td align="right">0.4550</td>
<td align="right">61.1095</td>
<td align="right">0.000000</td>
</tr>
<tr class="odd">
<td align="left">Urinary tract infection</td>
<td align="right">0.0341</td>
<td align="right">1.6465</td>
<td align="right">1.7080</td>
<td align="right">9.0587</td>
<td align="right">0.005251</td>
</tr>
</tbody>
</table>
<ul>
<li>In our comparative analysis of Lecanemab and Donanemab, we found
notable differences in specific adverse events. Lecanemab showed a
higher proportion of infusion-related reactions and urinary tract
infections, while Donanemab exhibited a higher incidence of ARIA-E.
These results highlight the distinct safety profiles of each drug,
emphasizing the need for tailored monitoring strategies based on the
unique risks associated with each treatment in managing Alzheimer’s
disease.</li>
</ul>
<pre class="r"><code>Don_result &lt;- read_excel(&quot;data/Donanemab.xlsx&quot;, sheet = &quot;result&quot;)

ggplot(Don_result, aes(x = as.factor(time), y = mean, fill = group, color = group)) +
  geom_point(position = position_dodge(0.9), size = 3, alpha = 0.5) +
  geom_errorbar(aes(ymin = ci_lower, ymax = ci_upper), position = position_dodge(0.9), width = 0.25) +
  facet_wrap(~outcome, scales = &quot;free_y&quot;) +
  labs(title = &quot;Mean with 95% CI over Time&quot;,
       x = &quot;Time&quot;,
       y = &quot;Mean&quot;) +
  theme_minimal()+
  theme(plot.title = element_text(hjust = 0.5)) +
  theme(legend.position = &quot;bottom&quot;) +
  guides(color = guide_legend(nrow = 2, byrow = TRUE))</code></pre>
<p><img src="Clinical_trials_files/figure-html/unnamed-chunk-22-1.png" width="90%" /></p>
</div>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->
<script>
$(document).ready(function () {
  window.initializeCodeFolding("hide" === "show");
});
</script>

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
